It is commonly accepted that anti-cancer agents regulate functions of the multidomain Bcl-2 family members (such as to activate Bax or to neutralize Bcl-2) via modulating the expression of short half-life proteins (e.g., BH3-only). The gene discussed is BAX; the disease is cancer.